Patents by Inventor Matthew W. Harding

Matthew W. Harding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS C VIRUS INFECTION BIOMARKERS
    Publication number: 20100028874
    Abstract: A signature set of genes associated with hepatitis C virus infection is described.
    Type: Application
    Filed: April 25, 2007
    Publication date: February 4, 2010
    Inventors: Ravi K. Ramachandran, Matthew W. Harding, Paul R. Caron, Martyn C. Botfield, Brian J. Hare, Raj Bandaru, Kevin M. Kelliher, Catharine N. Cornell
  • Methods for monitoring IL-18
    Publication number: 20090215856
    Abstract: This invention relates to methods for monitoring IL-18.
    Type: Application
    Filed: April 24, 2009
    Publication date: August 27, 2009
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Amit Roy, Matthew W. Harding, John Alam, John Randle
  • Biomarkers for Monitoring Impdh Pathway Inhibition
    Publication number: 20080318803
    Abstract: The present invention is directed to methods for ameliorating reproductive disorders. More specifically, the present invention describes methods and compositions for using IL-17 in the treatment of various infertility-related defects.
    Type: Application
    Filed: May 27, 2005
    Publication date: December 25, 2008
    Applicant: VERTEX PHARMACEUTICALS
    Inventors: Jugnu Jain, Matthew W. Harding, Ravi Ramachandran, Martyn Botfield
  • Isolation of an M.sub.r 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA
    Patent number: 5763590
    Abstract: An FK506 binding protein of mammalian origin of approximate size (M.sub.r) 52,000, isolated by FK506 affinity chromatography and a corresponding human cDNA of approximate size 2.2 Kb, isolated by screening a human placenta cDNA library with a DNA probe whose sequence predicts a consensus amino acid sequence present in five FKBP12 sequences and in the human FKBP13 sequence.
    Type: Grant
    Filed: November 9, 1994
    Date of Patent: June 9, 1998
    Assignee: Vertex Pharmaceuticals, Inc.
    Inventors: Debra A. Peattie, Matthew W. Harding, David J. Livingston
  • Carbamates and ureas as modifiers of multi-drug resistance
    Patent number: 5744485
    Abstract: The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: April 28, 1998
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Robert Edward Zelle, Matthew W. Harding
  • Biologically active acylated amino acid derivatives
    Patent number: 5723459
    Abstract: The present invention relates to novel compounds which possess a broad range of useful biological activities. These compounds can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. They can also suppress, modify, or significantly reduce an immune response, including an autoimmune response in a mammal. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, for use in multi-drug resistant cancer therapy, and for prevention or treatment of graft rejection and various autoimmune diseases.
    Type: Grant
    Filed: January 24, 1995
    Date of Patent: March 3, 1998
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: David M. Armistead, Matthew W. Harding, Jeffrey O. Saunders, Joshua S. Boger
  • Amino acid derivatives with improved multi-drug resistance activity
    Patent number: 5543423
    Abstract: The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: August 6, 1996
    Assignee: Vertex Pharmaceuticals, Incorporated
    Inventors: Robert E. Zelle, Matthew W. Harding
  • Immobilized cyclophilin and methods of using such
    Patent number: 5047512
    Abstract: Homogeneous cyclophilin, a soluble binding protein, having a specific binding activity of above 50 ug cyclosporin A per mg protein and a molecular weight of about 17,600 daltons, reversibly binds immunosuppressants or antibodies thereto such as cyclosporin or anti-cyclophilin. It is isolated from the cytosol of several different mammalian tissues and can be used in various diagnostic and purifications procedures.
    Type: Grant
    Filed: June 23, 1987
    Date of Patent: September 10, 1991
    Inventors: Robert E. Handschumacher, Matthew W. Harding, David W. Speicher
  • Fiber optic security system for protecting equipment from tampering
    Patent number: 5003292
    Abstract: The present invention is a fiber optic security system for protecting expensive equipment from tampering or theft. The fiber optic security system comprises an emitter for generating signals, a detector connected to an alarm for monitoring the signals and a sensing coupler or photon switch of novel design which is easily mounted to each piece of equipment that requires protection without defacing the equipment. The sensing coupler mounts the tips of optical fiber ends in a position aligned along a single axis to allow light generated by the emitter to pass through. Any attempt to remove the sensing coupler causes the tips to be misaligned and the light to be deflected. This causes an optic path interrupt and causes the detector to trigger an alarm.
    Type: Grant
    Filed: May 30, 1990
    Date of Patent: March 26, 1991
    Assignee: James E. Grimes Co., Inc.
    Inventors: Matthew W. Harding, Erick C. Christoferson, Edward Robak
  • Cyclophilin
    Patent number: 4722999
    Abstract: Homogeneous cyclophilin, a soluble binding protein, having a specific binding activity of above 50 ug cyclosporin A per mg protein and a molecular weight of about 17,600 daltons, reversibly binds immunosuppressants or antibodies thereto such as cyclosporin or anti-cyclophilin. It is isolated from thecytosol of several different mammalian tissues and can be used in various diagnostic and purifications procedures.
    Type: Grant
    Filed: May 3, 1985
    Date of Patent: February 2, 1988
    Assignee: Yale University
    Inventors: Robert E. Handschumacher, Matthew W. Harding, David W. Speicher